These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 19935091

  • 1. Combination of pharmacotherapy with electroconvulsive therapy in prevention of depressive relapse: a pilot controlled trial.
    Yildiz A, Mantar A, Simsek S, Onur E, Gökmen N, Fidaner H.
    J ECT; 2010 Jun; 26(2):104-10. PubMed ID: 19935091
    [Abstract] [Full Text] [Related]

  • 2. A randomized controlled trial comparing the memory effects of continuation electroconvulsive therapy versus continuation pharmacotherapy: results from the Consortium for Research in ECT (CORE) study.
    Smith GE, Rasmussen KG, Cullum CM, Felmlee-Devine MD, Petrides G, Rummans TA, Husain MM, Mueller M, Bernstein HJ, Knapp RG, O'Connor MK, Fink M, Sampson S, Bailine SH, Kellner CH, CORE Investigators.
    J Clin Psychiatry; 2010 Feb; 71(2):185-93. PubMed ID: 20193646
    [Abstract] [Full Text] [Related]

  • 3. Continuation electroconvulsive therapy with pharmacotherapy versus pharmacotherapy alone for prevention of relapse of depression: a randomized controlled trial.
    Nordenskjöld A, von Knorring L, Ljung T, Carlborg A, Brus O, Engström I.
    J ECT; 2013 Jun; 29(2):86-92. PubMed ID: 23303421
    [Abstract] [Full Text] [Related]

  • 4. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
    Amsterdam JD, Bodkin JA.
    J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
    [Abstract] [Full Text] [Related]

  • 5. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial.
    Kasper S, Volz HP, Möller HJ, Dienel A, Kieser M.
    Eur Neuropsychopharmacol; 2008 Nov; 18(11):803-13. PubMed ID: 18694635
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term follow-up after successful electroconvulsive therapy for depression: a 4- to 8-year naturalistic follow-up study.
    van Beusekom BS, van den Broek WW, Birkenhäger TK.
    J ECT; 2007 Mar; 23(1):17-20. PubMed ID: 17435567
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial.
    Rickels K, Montgomery SA, Tourian KA, Guelfi JD, Pitrosky B, Padmanabhan SK, Germain JM, Leurent C, Brisard C.
    J Clin Psychopharmacol; 2010 Feb; 30(1):18-24. PubMed ID: 20075643
    [Abstract] [Full Text] [Related]

  • 14. Predicting efficacy of electroconvulsive therapy in major depressive disorder.
    Tsuchiyama K, Nagayama H, Yamada K, Isogawa K, Katsuragi S, Kiyota A.
    Psychiatry Clin Neurosci; 2005 Oct; 59(5):546-50. PubMed ID: 16194256
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Long-term treatment strategies in major depression: a 2-year prospective naturalistic follow-up after successful electroconvulsive therapy.
    Martínez-Amorós E, Cardoner N, Soria V, Gálvez V, Menchón JM, Urretavizcaya M.
    J ECT; 2012 Jun; 28(2):92-7. PubMed ID: 22531201
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA, Masand PS, Pae CU, Peindl K, Hooper-Wood C, Mannelli P, Ciccone P.
    J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.